High plasma C-terminal FGF-23 levels predict poor outcomes in patients with chronic kidney disease superimposed with acute kidney injury

Yu-Hsing Chang*, Che-Hsiung Wu*, Nai-Kuan Chou, Li-Jung Tseng, i-Ping Huang, Chih-Hsien Wang, Vin-Cent Wu and Tzong-Shinn Chu

Abstract

Background: Elevated plasma C-terminal fibroblast growth factor-23 (cFGF-23) levels are associated with higher mortality in patients with chronic kidney disease (CKD) and acute kidney injury (AKI). Our study explored the outcome forecasting accuracy of cFGF-23 in critically ill patients with CKD superimposed with AKI (ACKD).

Methods: Urine and plasma biomarkers from 149 CKD patients superimposed with AKI before dialysis were checked in this multicenter prospective observational cohort study. Endpoints were 90-day mortality and 90 days free from dialysis after hospital discharge. Associations with study endpoints were assessed using hierarchical clustering analysis, the generalized additive model, the Cox proportional hazard model, competing risk analysis, and discrimination evaluation.

Results: Over a median follow up of 40 days, 67 (45.0%) patients died before the 90th day after hospital discharge and 39 (26.2%) progressed to kidney failure with replacement therapy (KFRT). Hierarchical clustering analysis demonstrated that cFGF-23 levels had better predictive ability for 90-day mortality than did other biomarkers. Higher serum cFGF-23 levels were independently associated with greater risk for 90-day mortality [hazard ratio (HR): 2.5; 95% confidence interval (CI) 1.5–4.1; \( p < 0.001 \)]. Moreover, adding plasma cFGF-23 to the Demirjian AKI risk score model substantially improved risk prediction for 90-day mortality than the Demirjian model alone (integrated discrimination improvement: 0.06; \( p < 0.05 \); 95% CI 0.02–0.10). The low plasma cFGF-23 group was predicted having more weaning from dialysis in surviving patients (HR = 0.53, 95% CI, 0.29–0.95, \( p = 0.05 \)).

Conclusions: In patients with ACKD, plasma cFGF-23 levels are an independent risk factor to forecast 90-day mortality and 90-day progression to KFRT. In combination with the clinical risk score, plasma cFGF-23 levels could substantially improve mortality risk prediction.

Keywords: acute kidney injury, biomarker, chronic kidney disease, fibroblast growth factor-23, mortality, neutrophil gelatinase-associated lipocalin, renal replacement therapy

Received: 28 May 2020; revised manuscript accepted: 14 September 2020.
uremic toxins and excessive fluid, it can also potentially cause adverse outcomes through inexorable therapeutic side effects.\(^7\) Recent evidence indicates that in early-stage AKI, early biomarker-based intervention can improve prognosis;\(^8\) however, the optimal RRT timing and strategy in critically ill patients with ACKD remains unknown because of the paucity of research.\(^1,6,9\)

AKI, particularly dialysis-requiring AKI, accelerates the progression of established CKD and increases kidney failure with replacement therapy (KFRT) and mortality risks.\(^6,9\) Pre-existing CKD exacerbates kidney microvascular rarefaction, failed tubular redifferentiation, cell-cycle regulation disruption, hypertension, and proteinuria after AKI.\(^10\) An efficient kidney biomarker that can aid in estimating dialysis initiation timepoint in patients with CKD and acute deterioration of kidney function has not been identified. Fibroblast growth factor (FGF)-23, secreted mainly by osteocytes and possibly osteoblast, has several pathophysiological clinical implications in CKD, AKI, and cardiovascular disease.\(^11\) Increase in FGF-23 levels is potentially one of the earliest biochemical abnormalities in CKD mineral bone disorder. Elevated FGF-23 is also related to accelerated atherosclerosis and endothelial dysfunction, promoting the development of cardiovascular complications in uremia. It is considered to be a predictor reflecting tubular dysfunction, and associated with a higher AKI risk\(^12\) and with death or the need for RRT in patients with AKI.\(^13,14\) Multiple FGF-23 peptides are present in the circulation, including full-length FGF-23, N-terminal fragments and C-terminal fragments. C-terminal assays use antibodies that target epitopes in the C terminus and thus detect both full-length FGF-23 and its C-terminal fragments. Intact FGF-23 assays use antibodies that target epitopes flanking the FGF-23 cleavage site and thus can only detect full-length FGF-23.\(^15\)

CKD has strong effects on the performance of AKI damage biomarkers.\(^16,17\) A newer, more precise prediction model for the outcomes of patients with ACKD is necessary. Thus, in this, a prospective cohort study, we evaluate FGF-23 as an early biomarker for dialysis initiation and its predictive ability for mortality and long-term dialysis in a critically ill ACKD population requiring RRT.

**Materials and methods**

**Study population**

We prospectively enrolled CKD patients undergoing RRT for AKI in multiple intensive care units (ICUs) from the National Taiwan University Study Group on Acute Renal Failure\(^18–22\) over January 2011 to April 2016. Pre-existing CKD was defined as a Modification of Diet in Renal Disease Study equation (MDRD)-derived estimated glomerular filtration rate (eGFR) of \(\leq 60\) ml/min per 1.73 m\(^2\) for \(>3\) months, abnormal kidney ultrasound results within 1 year before enrollment, or both, according to the CKD guideline of Kidney Disease: Improving Global Outcomes (KDIGO). Baseline serum creatinine level (sCr) was the nadir value obtained after the previous admission in patients who had more than one admission within 1 year predating the index admission,\(^8\) or in those without a previous admission, it was the mean outpatient value 180 days before index admission.\(^23\) Peak sCr was defined as the highest sCr before RRT initiation in the ICU.

The study excluded patients who had undergone nephrectomy, kidney transplantation, or RRT treatment; ICU or hospital length of stay of \(<2\) days or \(>180\) days during the index hospitalization; and those aged \(<18\) years. Patients with AKI caused by obstruction, glomerulonephritis, vasculitis, interstitial nephritis, pigmentation, hemolytic uremic syndrome, thrombotic thrombocytopenic purpura, or without previous baseline creatinine were also excluded.

**Ethics and consent**

This study was approved by the research ethics review board of National Taiwan University Hospital (201105040RC) along with established written informed consent. This research was carried out in accordance with the approved guidelines. Written informed consent was obtained from all participants before inclusion. This study was conducted in accordance with the Declaration of Helsinki.

**Data collection**

Demographic data were collected, and comorbidities and etiologies of AKI were documented. The patients’ disease severity before dialysis was reported using their Sequential Organ Failure
Assessment (SOFA) score, Acute Physiology and Chronic Health Evaluation II (APACHE II) score, Logistic Organ Dysfunction System (LODS) Score, Multiple Organ Dysfunction Score (MODS), and Demirjian AKI score.24

**Outcome of interests**

The index date was the day of initiation of RRT, and the primary outcomes were 90-day mortality and 90 days free from dialysis after hospital discharge. All patients were followed until death or for a timespan exceeding 90 days after discharge, whichever occurred first. Successful withdrawal from dialysis was defined as survival without dialysis at the end of study.

**Indication for RRT**

sCr is greatly affected by muscle wasting and body fluid status in critically ill patients. The predetermined indications for RRT were the same as previous reports,18,19,22 including: (a) presence of azotemia [blood urea nitrogen (BUN) >80 mg/dl and sCr >2 mg/dl] with uremic symptoms (encephalopathy, pericarditis, or pleurisy); (b) oliguria (urine output <400 ml/24 h) or anuria refractory to diuretics; (c) fluid overload refractory to diuretics with a central venous pressure >12 mmHg or pulmonary edema with a PaO₂/FiO₂ <300 mmHg; (d) hyperkalemia (serum potassium level >5.5 mmol/l) refractory to medical treatment; or (e) metabolic acidosis (arterial pH <7.2).

RRT modalities in each patient depended on the attending physician’s clinical judgment and were adjusted according to the hemodynamic evolution by our critical care nephrologist.25

**Kidney biomarker measurement**

Blood and urine creatinine as well as plasma and urinary C-terminal fibroblast growth factor-23 (cFGF-23)/intact FGF-23 (iFGF-23), urinary kidney injury molecule-1 (KIM-1), urinary neutrophil gelatinase-associated lipocalin (NGAL), and urinary tissue inhibitor metalloproteinase-2 (TIMP-2) and insulin-like growth-factor-binding protein 7 (IGFBP7) levels at dialysis initiation were measured (start of the study). All these biomarkers were expected to increase after AKI. The plasma samples were collected just before dialysis and stored at −80°C until further processing.

Kidney biomarker levels were assessed with a human FGF-23 C-terminal enzyme-linked immunosorbent assay (ELISA) kit (Immutopics; San Clemente, CA, USA; reference range 26–110 kRU/ml), a human KIM-1 ELISA kit (R&D Systems, Minneapolis, MN, USA), a lipocalin-2/NGAL ELISA and a human TIMP-2 ELISA kits (both from R&D Systems), and a human IGFBP-7 ELISA kit (Millipore, Billerica, MA, USA). The cFGF-23 and iFGF-23 values were expressed in relative units (RU)/ml and pg/ml, respectively. The coefficient of variation was 4.4% for iFGF-23 and 4.0% for cFGF-23. The lower limits for detection of cFGF-23, iFGF-23, KIM-1, TIMP2, and NGAL were 1.5 RU/ml, 1.5 pg/ml, 0.046 ng/ml, 0.064 ng/ml, and 0.04 ng/ml, respectively, as described by the manufacturer’s protocol and performed in duplicate. All biomarkers were measured from frozen aliquots, which were not exposed to any additional freeze–thaw cycles. The technicians performing the biomarker measurements were blinded to patients’ clinical information.14

1,25-dihydroxyvitamin D was measured using a DiaSorin radioimmunoassay assay kit (Stillwater, MN, USA) and total 1,25-hydroxyvitamin D was measured using an electrochemiluminescence assay kit (Elecsys Vitamin D total, Cobas, Roche©, USA).

Assays were completed as described by the manufacturers’ protocols. Each measurement was performed in duplicate and the mean of the two readings used for the statistical analysis. Creatinine levels were measured using the Jaffe assay, with standardization to isotope dilution mass-spectrometry-traceable reference.14,26

**Statistical analysis**

We used R (version 3.4.2; Free Software Foundation, Inc., Boston, MA, USA) for data analysis, and figure plotting for survival analysis, including the hierarchical clustering analysis, Kaplan–Meier curve, Cox proportional hazard model, competing risk analysis, integrated discriminative index, and a vector generalized additive model (GAM).

Continuous data are expressed as mean ± standard deviation, whereas categorical data are expressed as number (percentage). The χ² or Fisher’s exact test were used for comparison of categorical variables; Student’s t test was used for continuous variables.
Hierarchical clustering analysis was performed using the cluster program, and the results were visualized using the Treeview program. The biomarkers were arranged in such a way that the most similar expression profiles were placed next to each other. In the color scheme, strong positive staining is indicated as a red cube, weak positive staining as a white cube and negative staining as a blue cube. We used a GAM (with spline) incorporating the subject-specific (longitudinal) random effects and adjusted for disease severity, baseline eGFR, sex, and age to predict the outcomes. The optimal cutoff value defined as the log odd equaling to zero. Because of the high mortality rate among our patients, competing risk analysis by the Fine and Gray model for consideration of the subdistribution hazard was used to evaluate cumulative incidence of free-from RRT in the nonmortality group. Finally, we calculated the net reclassification improvement (NRI) and integrated discrimination improvement (IDI) to estimate overall improvement in reclassification with biomarkers adding to clinical variables. A p < 0.05 was considered significant.

Results

Clinical characteristics

In total, 149 patients with CKD were eligible for this study. Their mean age was 71.8 ± 13.5 years; of them, 65.8% were men, and 55% had diabetes mellitus. The underlying comorbidities were comparable for both groups. The mean eGFR at baseline was 31.0 ± 15.9 ml/min/1.73 m². Mean disease severity as assessed using SOFA scores, APACHE II scores, LODS scores, MODS, and Demirjian AKI model scores was 10.1, 17.4, 8.7, 7.5, and 22.0, respectively.

The major etiology of AKI in our patients was shock (53.7%), followed by sepsis (34.2%). The most frequent indication for dialysis initiation was azotemia (49.7%), followed by fluid overload (42.3%; Table 1).

Outcomes of interest

The 90-day mortality rate after hospital discharge was 45%. Table 1 presents the baseline condition prior to RRT and disease severity at dialysis initiation categorized according to 90-day mortality. The mortality group was older and had less urine output, higher baseline eGFR, lower BUN and sCR levels, higher inotropic equivalents, higher disease severity score at dialysis initiation, and a higher percentage of patients receiving mechanical ventilation (Table 1). The levels of biomarkers including plasma cFGF-23, urinary NGAL, urinary TIMP2 and IGFBP7, and urinary KIM-1 were higher, but plasma iFGF-23 levels were lower in the mortality group compared with the survival group.

The relationship of the biomarkers with 90-day mortality

Given the potential for collinearity between some of the biomarkers, we performed an unsupervised cluster analysis to determine the relationship of the biomarkers to 90-day mortality (Figure 1). Plasma cFGF-23 was nearest to ‘90-day mortality’, and may explain their strong predictive ability for 90-day mortality. Therefore, plasma cFGF-23 was selected for further analysis.

Using the GAM to stratify cFGF-23 and predict outcomes

We used GAM to decide the log[cFGF-23] non-linear effect on the hazard ratio of the 90-day mortality with adjustments for all variables listed in Table 1. The GAM plot was generated thereafter; it revealed a positive correlation between increased log[cFGF-23] levels at dialysis initiation and the odds risk of 90-day mortality (Figure 2). The optimal cutoff was arbitrarily determined to be 3.42 (= 2512 RU/ml). Therefore, we stratified our ACKD patients into two groups: ≥3.42 (high level; hazard ratio of 90-day mortality >1) and <3.42 (low level; hazard ratio of 90-day mortality <1).

Patients with ACKD and high plasma cFGF-23 levels were younger, with higher baseline eGFR, lower BUN and Cr levels, higher inotropic equivalents, and more severe disease severity at dialysis initiation, along with higher 90-day mortality and lower dialysis weaning rate (Table 2).

The Cox proportional hazard model revealed that patients with ACKD with high plasma cFGF-23 levels had higher 90-day mortality (HR, 2.49; 95% CI 1.5–4.1; p < 0.001) than did the low plasma cFGF-23 group (Table 3). The median survival rate was 36 days for the high plasma cFGF-23 group and 127 days for the low plasma cFGF-23 group [Figure 3(a)].
Table 1. Clinical characteristics of patient groups by 90-day mortality after index hospital discharge.

| Patient characteristics | All patients | 90-day mortality | Non mortality | p value |
|-------------------------|--------------|------------------|---------------|---------|
| **n**                   | 149          | 67 (45.0)        | 82 (55.0)     |         |
| **Age, years**          | 71.8 (13.5)  | 73.6 (13.3)      | 66.9 (13.0)   | <0.001  |
| **Sex (male) [%]**      | 98 (65.8)    | 41 (61.2)        | 57 (69.5)     | 0.373   |
| **Baseline eGFR, ml/min/1.73 m² (SD)** | 31.0 (15.9)  | 36.3 (13.9)      | 26.7 (16.2)   | <0.001  |
| **CKD, stage 3 [%]**    | 72 (48.3)    | 42 (62.7)        | 30 (36.6)     | <0.001  |
| **CKD, stage 4 [%]**    | 52 (34.9)    | 23 (34.3)        | 29 (35.4)     |         |
| **CKD, stage 5 [%]**    | 25 (16.8)    | 2 (3.0)          | 23 (28.0)     |         |

| **Comorbidities**       |              |                  |               |         |
| **CAD [%]**             | 30 (20.1)    | 17 (25.4)        | 13 (15.9)     | 0.216   |
| **Diabetes mellitus [%]** | 82 (55.0)    | 34 (50.7)        | 48 (58.5)     | 0.432   |
| **Diabetes mellitus with insulin use [%]** | 39 (26.2)    | 15 (22.4)        | 24 (29.3)     | 0.445   |
| **COPD [%]**            | 7 (4.7)      | 5 (7.5)          | 2 (2.4)       | 0.293   |
| **Liver cirrhosis [%]** | 4 (2.7)      | 2 (3.0)          | 2 (2.4)       | 0.761   |
| **Congestive heart failure [%]** | 113 (75.8)  | 52 (77.6)        | 61 (74.4)     | 0.624   |
| **NYHA I [%]**          | 56 (37.6)    | 27 (40.3)        | 29 (35.4)     |         |
| **NYHA II [%]**         | 35 (23.5)    | 18 (26.9)        | 17 (20.7)     |         |
| **NYHA III [%]**        | 18 (12.1)    | 6 (9.0)          | 12 (14.6)     |         |

| **Laboratory data at dialysis initiation** |              |                  |               |         |
| **Creatinine (mg/dl)** | 4.7 (2.5)    | 4.0 (2.0)        | 5.2 (2.7)     | <0.001  |
| **LVEF ≤35 [%]**       | 19 (12.8)    | 7 (10.4)         | 11 (13.4)     | 0.807   |
| **35% < LVEF ≤55 [%]** | 25 (16.8)    | 14 (20.9)        | 10 (12.2)     |         |
| **55% < LVEF [%]**     | 39 (26.2)    | 18 (26.9)        | 21 (25.6)     |         |
| **Pre-dialysis BW (kg)** | 67.3 (14.0)  | 66.4 (12.5)      | 68.1 (15.1)   | <0.001  |
| **24 h urine output (ml/24 h)** | 574.8 (617.8) | 446.4 (463.3) | 679.7 (705.5) | <0.001  |
| **BUN (mg/dl)**        | 85.8 (48.1)  | 81.8 (49.7)      | 89.1 (46.8)   | <0.001  |
| **Initial inotropic equivalents** | 6.5 (10.3)  | 10.0 (12.7)      | 3.7 (6.6)     | <0.001  |

| **Biomarker at initializing dialysis** |              |                  |               |         |
| **Plasma cFGF-23 (RU/ml)** | 2395.5 (2050.1) | 3078.8 (2443.2)  | 1837.2 (1453.8) | <0.001  |
| **Urinary NGAL (ng/ml)**  | 198.1 (81.9)  | 209.0 (67.7)     | 189.3 (91.4)  | <0.001  |
| **Urinary TIMP2 and IGFBP7** | 1099.1 (1448.9) | 1284.6 (1658.8) | 947.5 (1241.8) | <0.001  |

(Continued)
| Patient characteristics                  | All patients | 90-day mortality | Non mortality | p value |
|-----------------------------------------|--------------|------------------|---------------|---------|
| Urinary KIM-1 (ng/ml)                   | 5.8 (5.6)    | 6.4 (6.0)        | 5.3 (5.4)     | <0.001  |
| Plasma iFGF-23 (pg/ml)                  | 327.7 (566.4)| 213.6 (276.2)    | 613.0 (939.0) | 0.002   |
| Urine cFGF-23/urine Cr                  | 93.8 (199.7) | 126.6 (268.7)    | 67.0 (111.6)  | <0.001  |
| Vitamin D, ng/ml                        | 11.8 (5.2)   | 13.7 (6.3)       | 10.2 (3.9)    | < 0.001 |
| Activated vitamin D, pg/ml              | 24.9 (5.3)   | 27.3 (5.7)       | 23.0 (4.5)    | <0.001  |
| **Indications for dialysis (%)**        |              |                  |               |         |
| Azotemia                                | 74 (49.7)    | 32 (47.8)        | 42 (51.2)     | 0.799   |
| Fluid overload                          | 63 (42.3)    | 30 (44.8)        | 33 (40.2)     | 0.696   |
| Electrolyte imbalance                   | 10 (6.7)     | 2 (3.0)          | 8 (9.8)       | 0.189   |
| Acidosis                                | 26 (17.4)    | 13 (19.4)        | 13 (15.9)     | 0.726   |
| **Etiology of ACKD (%)**                |              |                  |               |         |
| Shock                                   | 80 (53.7)    | 45 (67.2)        | 35 (42.7)     | 0.005   |
| Sepsis                                  | 51 (34.2)    | 34 (50.7)        | 17 (20.7)     | 0.0002  |
| Drug                                    | 3 (2.0)      | 3 (4.5)          | 0 (0.0)       | 0.177   |
| Contrast                                | 23 (15.4)    | 7 (10.4)         | 16 (19.5)     | 0.195   |
| **Intervention during hospitalization** |              |                  |               |         |
| CABG (%)                                | 17 (11.4)    | 10 (14.9)        | 7 (8.5)       | 0.336   |
| Valve surgery (%)                       | 11 (7.4)     | 8 (11.9)         | 3 (3.7)       | 0.108   |
| Mechanical Ventilation (%)              | 98 (65.8)    | 53 (79.1)        | 45 (54.9)     | 0.003   |
| **Disease severity at initializing dialysis** |          |                  |               |         |
| SOFA score                              | 10.1 (3.8)   | 12.1 (4.0)       | 8.5 (2.9)     | <0.001  |
| APACHE II                               | 17.4 (6.2)   | 19.8 (6.7)       | 15.5 (4.9)    | <0.001  |
| LODS                                    | 8.7 (2.2)    | 9.6 (2.5)        | 8.0 (1.5)     | <0.001  |
| MODS                                    | 7.5 (4.0)    | 9.3 (3.9)        | 6.1 (3.5)     | <0.001  |
| Demirjian AKI model                     | 22.0 (7.3)   | 25.4 (6.9)       | 19.2 (6.3)    | < 0.001 |
| Length of hospitalization (days)        | 50.8 (49.3)  | 54.3 (57.7)      | 48.0 (41.3)   | <0.001  |

<sup>$^*$</sup>Continuous data are expressed as mean ± standard deviation, whereas categorical data are expressed as number (percentage).

ACKD, acute kidney injury on chronic kidney disease; AKI, acute kidney injury; APACHE II, Acute Physiology and Chronic Health Evaluation; BUN, blood urea nitrogen; BW, body weight; CABG, coronary artery bypass graft; CAD, coronary artery disease; cFGF-23, C-terminal fibroblast growth factor 23; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; iFGF-23, intact fibroblast growth factor 23; IGFBP7, insulin-like growth-factor–binding protein 7; KIM-1, kidney injury molecule-1; LODS, Logistic Organ Dysfunction Score; LVEF, left-ventricle ejection fraction; MODS, Multiple Organ Dysfunction Score; NGAL, neutrophil-gelatinase-associated lipocalin; NYHA, New York Heart Association; SD, standard deviation; SOFA, Sequential Organ Failure Assessment; TIMP2, tissue inhibitor of metalloproteinase 2.
In competing risk analysis, mortality was censored, and the low plasma cFGF-23 group was predicted having more weaning from dialysis in surviving patients [HR = 0.53; 95% CI 0.29–0.95; p = 0.05; Additional File 1: Table S1; Figure 3(b)].

**Addition of biomarkers to Demirjian model and mortality prediction**

We assessed reclassification and evaluated any improvement in the predictive capacity of biomarker for 90-day mortality prediction by adding it to the Demirjian AKI risk model. The combination...
of cFGF-23 with Demirjian model led to a significant increase in risk stratification (NRI = 0.61 (0.31–0.92); p < 0.05; NRI reclassification table was shown in Additional File 1: Table S2). Simultaneously, the IDI was significant at 0.06 (95% CI 0.02–0.10; p < 0.05). The combination of other biomarkers with the Demirjian model was not significant for NRI and IDI reclassification in forecasting 90-day mortality (Table 4).

**Discussion**

This study evaluated the plasma cFGF-23 levels elevated in patients with AKI and CKD at ACKD status and its discriminative ability for outcome prediction. In critical CKD patients who required dialysis, higher plasma cFGF-23 levels could predict patient mortality and less kidney recovery in survivals. Notably, plasma cFGF-23 integrated into the AKI risk predicting score significantly enhanced the accuracy of risk stratification in CKD patients. Thus, plasma cFGF-23 can be used as an early determinant of prognosis in ICU patients with ACKD at dialysis initiation and as a kidney recovery marker.

**FGF-23 as a prognostic marker of adverse outcomes in patients with ACKD**

Our results revealed that plasma cFGF-23 has better discriminative ability for 90-day mortality than NGAL in AKI for patients with CKD. A study established that NGAL increases considerably with the reduction in GFR.\(^3\) NGAL alone is insufficient to discriminate de novo AKI from CKD without AKI.\(^3\) Kim et al. reported that the interval change of NGAL during the first 48 h after AKI onset was much lower in the ACKD group than in the AKI group.\(^3\) Pre-existing poor kidney function can interfere with the performance of biomarkers.\(^16\) The proportion of stage 4 and 5 CKD in our cohort was not significantly different between patients with high and low plasma cFGF-23 levels at dialysis initiation (Table 2). Therefore, plasma cFGF-23, the levels of which increase in patients with AKI, has no significant interaction with baseline eGFR when predicting in-hospital mortality. This interpretation is concordant with the result of a previous study, which indicated that plasma cFGF-23 is significantly associated with death even after adjustments for CKD.\(^13\) Brown et al. also demonstrated that FGF-23 adjusted for baseline eGFR is independently associated with AKI risk.\(^12\)

In our study, we discovered that non-survivors had significantly elevated FGF-23 levels compared with survivors. This result is consistent with that of ATN (ARF Trial Network) study, which included patients with AKI requiring RRT, that reported patients in the highest compared with the lowest quartiles of cFGF-23 had 3.84
Table 2. Clinical characteristics of patients with high versus low plasma cFGF-23 at initialization of dialysis.

| Patient characteristics | High cFGF-23 | Low cFGF-23 | p value |
|-------------------------|-------------|-------------|---------|
| n [%]                   | 55 [36.9]   | 94 [63.1]   |         |
| Age, years              | 68.4 [15.1] | 70.8 [12.5] | <0.001  |
| Sex, male [%]           | 31 [56.4]   | 68 [72.3]   | 0.009   |
| Baseline eGFR [ml/min/1.73 m²] | 34.2 [15.2] | 29.4 [16.1] | <0.001  |
| CKD, stage 3 [%]        | 31 [56.4]   | 41 [37.2]   | 0.130   |
| CKD, stage 4 [%]        | 17 [30.9]   | 35 [37.2]   |         |
| CKD, stage 5 [%]        | 7 [12.7]    | 18 [19.1]   |         |
| Comorbidities           |             |             |         |
| CAD [%]                 | 11 [20.0]   | 19 [20.2]   | 0.999   |
| Diabetes mellitus [%]   | 30 [54.5]   | 52 [55.3]   | 0.999   |
| Diabetes mellitus with insulin use [%] | 15 [27.3] | 24 [25.5]  | 0.188   |
| COPD [%]                | 5 [9.1]     | 2 [2.1]     | 0.124   |
| Liver cirrhosis [%]     | 4 [7.3]     | 0 [0.0]     | 0.034   |
| Congestive heart failure [%] |         |             | 0.532   |
| NYHA I [%]              | 21 [38.2]   | 35 [37.2]   |         |
| NYHA II [%]             | 13 [23.6]   | 22 [23.4]   |         |
| NYHA III [%]            | 7 [12.7]    | 11 [11.7]   |         |
| Laboratory data at dialysis initiation |             |             |         |
| Creatinine [mg/dl]      | 4.4 [2.7]   | 4.7 [2.4]   | <0.001  |
| LVEF <= 35% [%]         | 9 [16.4]    | 9 [9.6]     | 0.253#2 |
| 35 < LVEF <= 55% [%]    | 9 [16.4]    | 15 [16.0]   |         |
| 55% < LVEF [%]          | 13 [23.6]   | 26 [27.7]   |         |
| Pre-dialysis BW [kg]    | 65.8 [12.1] | 68.0 [15.0] | <0.001  |
| 24 h urine output [ml/24 h] | 521.9 [620.0] | 604.8 [617.8] | <0.001 |
| BUN [mg/dl]             | 84.0 [53.0] | 86.0 [45.2] | <0.001  |
| Initial inotropic equivalents | 9.1 [12.0] | 5.3 [9.0]  | <0.001  |
| Biomarker at dialysis initiation |             |             |         |
| Urinary NGAL [ng/ml]    | 196.3 [90.8] | 201.2 [76.6] | <0.001  |
| Urinary TIMP2 and IGFBP7 | 1329.8 [1593.9] | 998.2 [1355.7] | <0.001  |
| Urinary KIM-1 [ng/ml]   | 7.3 [6.4]   | 5.0 [5.0]   | <0.001  |

(Continued)
### Table 2. (Continued)

| Patient characteristics | High cFGF-23 | Low cFGF-23 | p value |
|-------------------------|-------------|-------------|---------|
| Vitamin D, ng/ml        | 9.5 (3.9)   | 12.6 (5.6)  | <0.001  |
| Activated vitamin D, pg/ml | 26.5 (5.7) | 24.4 (5.5)  | <0.001  |

#### Indications for dialysis (%)

|                          | High cFGF-23 | Low cFGF-23 | p value |
|--------------------------|-------------|-------------|---------|
| Azotemia                 | 26 (47.3)   | 48 (51.1)   | 0.782   |
| Fluid overload           | 25 (45.5)   | 38 (40.4)   | 0.669   |
| Electrolyte imbalance    | 1 (1.8)     | 9 (9.6)     | 0.137   |
| Acidosis                 | 12 (21.8)   | 14 (14.9)   | 0.395   |

#### Etiology of ACKD (%)

|                          | High cFGF-23 | Low cFGF-23 | p value |
|--------------------------|-------------|-------------|---------|
| Shock                    | 34 (61.8)   | 46 (48.9)   | 0.177   |
| Sepsis                   | 21 (38.2)   | 30 (31.9)   | 0.549   |
| Drug                     | 1 (1.8)     | 2 (2.1)     | 0.999   |
| Contrast                 | 11 (20.0)   | 12 (12.8)   | 0.345   |

#### Intervention during hospitalization

|                          | High cFGF-23 | Low cFGF-23 | p value |
|--------------------------|-------------|-------------|---------|
| CABG (%)                 | 9 (16.4)    | 30 (31.9)   | 0.235   |
| Valve surgery (%)        | 4 (7.3)     | 7 (7.4)     | 0.999   |
| Mechanical ventilation (%)| 37 (67.3)  | 61 (64.9)   | 0.907   |

#### Disease severity at initializing dialysis (SD)

|                          | High cFGF-23 | Low cFGF-23 | p value |
|--------------------------|-------------|-------------|---------|
| SOFA score               | 11.0 (4.0)  | 9.7 (3.7)   | <0.001  |
| APACHE II                | 17.5 (7.1)  | 17.2 (5.6)  | <0.001  |
| LODS score               | 9.0 (2.3)   | 8.5 (2.0)   | <0.001  |
| MODS score               | 8.4 (4.4)   | 7.1 (3.7)   | <0.001  |
| Demirjian AKI model      | 22.9 (7.4)  | 21.4 (7.2)  | <0.001  |
| Length of hospitalization (days) | 42.3 (36.1) | 56.0 (56.1) | <0.001 |

Continuous data are expressed as mean ± standard deviation, whereas categorical data are expressed as number (percentage).

ACKD, acute kidney injury on chronic kidney disease; AKI, acute kidney injury; APACHE II, Acute Physiology and Chronic Health Evaluation; BUN, blood urea nitrogen; BW, body weight; CABG, coronary artery bypass graft; CAD, coronary artery disease; cFGF-23, C-terminal fibroblast growth factor 23; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; iFGF-23, intact fibroblast growth factor 23; IGFBP7, insulin-like growth-factor-binding protein 7; KIM-1, kidney injury molecule-1; LODS, Logistic Organ Dysfunction Score; LVEF, left-ventricle ejection fraction; MODS, Multiple Organ Dysfunction Score; NGAL, neutrophil-gelatinase-associated lipocalin; NYHA, New York Heart Association; SD, standard deviation; SOFA, Sequential Organ Failure Assessment; TIMP2, tissue inhibitor of metalloproteinase 2.

times higher odds of death.\textsuperscript{36} FGF-23 has an immunomodulatory property: it acts directly on neutrophil and dampens host defense through direct interference with chemokine signaling and integrin activation, thus impairing host defense.\textsuperscript{37} cFGF-23 concentration may reflect a common
mechanism associated with adverse outcomes, such as inflammation. FGF-23 could promote inflammation by inducing the expression of IL-6 and C-reactive protein, resulting in a positive feedback vicious cycle. Silswal et al. provided evidence that high FGF-23 levels further impair endothelium-dependent vasorelaxation by reducing nitric oxide bioavailability and increasing superoxide levels that would contribute to cardiovascular dysfunction.

Inflammation stimulates a proportional increase in FGF-23 transcription and cleavage. Consequently, although cFGF-23 levels increase, iFGF-23 levels are only moderately increased. By contrast, FGF-23 cleavage is downregulated or impaired in CKD. Therefore, both cFGF-23 and iFGF-23 levels are progressively increased. In our cohort, plasma cFGF-23 levels were higher, but iFGF-23 levels were lower in the mortality group than in the survival group. This suggests that elevated cFGF-23 level in the mortality group was attributable to increased cFGF-23 production and cleavage at ACKD status.

**Mortality risk of patients with ACKD**

A population-based study revealed that the 90-day mortality rate of critically ill patients with dialysis-requiring AKI was 60%. In our cohort, 45% patients with ACKD requiring dialysis died before the 90th day after hospital discharge. This finding is concordant with studies that suggested a history of CKD might improve the outcome of patients with AKI. The Program to Improve Care in Acute Renal Disease study reported that critically ill patients with AKI on CKD, despite having increased age and more extensive comorbidities than patients with pure AKI, had a lower mortality rate but were more likely to be dialysis dependent at hospital discharge. Pan et al. demonstrated that the in-hospital mortality rate of pure AKI patients was 3.82-fold higher than that of AKI on CKD patients, and pre-existing CKD was an independent protective factor against death. Groeneveld et al. observed that pre-existing CKD reduced 90-day mortality risk in patients with AKI. Cerda et al. found that higher sCR levels at start of dialysis were associated with longer survival in critically ill patients with AKI, and this may be due to pre-existing CKD, better nutrition, or lesser volume overload. Further research may be necessary to determine whether incorporating CKD history into the AKI staging system could improve prognosis prediction.

**Dialysis dependence risk in patients with ACKD**

Dialysis dependence is a rare outcome among patients with AKI without underlying CKD. When occurring in patients with CKD, AKI may accelerate CKD progression and increase KFRT risk. AKI incidence and severity increases substantially with lower levels of baseline eGFR, with the highest KFRT risk after AKI noted in patients with advanced CKD. Of 82 survivors of ACKD in our study, 39 required long-term dialysis 90 days after discharge. This is consistent with a previous report where 49% of CKD patients fell into KFRT, indicating that superimposed AKI episodes among patients with pre-existing CKD was a strong independent risk factor for KFRT.

**Table 3. Multivariate Cox proportional model for mortality and composite outcomes at 90 days after discharge.**

| Variables                          | 90-day mortality |       |       |
|-----------------------------------|------------------|-------|-------|
|                                   | HR   | 95% CI | p    |
| Age (per year)                    | 1.02 | 1.00–1.04 | 0.03  |
| Initial SOFA (per score)          | 1.20 | 1.12–1.28 | <0.001|
| cFGF-23 group (high versus low)   | 2.35 | 1.41–3.92 | <0.001|
| Baseline eGFR at dialysis initiation | 1.03 | 1.01–1.04 | 0.01  |

Significant risks are shown.
All the univariate significant and nonsignificant relevant covariates, including baseline comorbidities, sex, indications for dialysis, and intervention during hospitalization listed in Table 1.
CI, confidence interval; eGFR, estimated glomerular filtration rate; HR, hazard ratio; cFGF-23, log C-terminal fibroblast factor-23; SOFA, Sequential Organ Failure Assessment.
Care of patients with acute kidney disease

AKI that has not recovered within a week is termed acute kidney disease (AKD). AKD is assigned stages 1–3 on the basis of the occurrence of KDIGO AKI criteria during the 7–90-day period after the initial AKI. Predicting 90-day mortality after severe AKI is valuable for risk stratification and clinical decision making in caring for patients with AKD. However, no previous prediction models have been focused on 90-day mortality. The combination of clinical models (Demirjian score) and biomarkers (FGF-23) could more...
reliably anticipate 90-day mortality risk during the AKD period and thus improve care for patients.

A key difficulty was noted: patients with CKD are often exposed to potentially nephrotoxic drugs as well as surgical and septic insults. All clinicians should recognize the increased risk and significance of an acute deterioration in kidney function, particularly dialysis-requiring ACKD with poor outcome. However, whether cFGF-23 can be used as a surrogate marker for improving dialysis initiation timing must be validated externally.

Limitations
Our study has several limitations. First, some confounders were not measured and thus warrant consideration. Second, the Demirjian AKI score outcome is 60-day mortality. We measured several biomarkers at dialysis initiation in our cohort. Demirjian’s model also collected variables at dialysis initiation, while other models collected variables at nephrologist consultation or at AKI diagnosis. Therefore, we tended to examine the discriminative ability for 90-day mortality prediction of Demirjian’s model, and to explore whether adding a biomarker to the Demirjian AKI risk score model could substantially improve risk prediction for 90-day mortality or not. In addition, the use of timepoint-only measurement of cFGF-23 instead of sequential cFGF-23 measurement provided only cross-sectional data. Also, although the patients were enrolled in multiple ICUs, the number of patients might be insufficient to determine plasma FGF-23 generalizability and reliability. Finally, whether cFGF-23 is simply a risk marker or a contributor to adverse outcome remains unclear. Further research clarifying the predictive value of plasma cFGF-23 in different patient populations and evaluate whether a reduction of plasma cFGF-23 levels is beneficial for patients is required.

Conclusion
cFGF-23 is a promising biomarker applied in patients with dialysis-requiring ACKD to predict 90-day prognosis after discharge and could direct decision making. Our finding suggests that measurements of plasma cFGF-23 levels in ACKD before dialysis may enable the identification of a high-risk population. cFGF-23 level is also a strong prognostic factor for ACKD patients requiring dialysis, adding information to an AKI risk score.

Author contributions
YH contributed to data interpretation, drafting of the manuscript and performed statistical analysis. WC contributed to data collection and data interpretation and critical revision of the manuscript. VC chaired the group, conceived and designed the

| Table 4. Discriminative improvement of biomarkers added to Demirjian score for prediction of 90-day mortality. |
|----------------------------------------------------------|
| **Model**                                      | **NRI$ \times 100$ (95% CI) | $p$ | **# IDI (95% CI) | $p$ |
| Demirjian score                                        | 0.61 (0.31–0.92) | <0.05 | 0.06 (0.02–0.09) | <0.05 |
| Demirjian score + cFGF-23                              | 0.57 (0.28–0.86) | <0.05 | 0.10 (0.02–0.17) | 0.03 |
| Demirjian score + KIM                                  | -0.11 (−0.40 to 0.18) | 0.46 | 0.0005 (−0.003 to 0.004) | 0.79 |
| Demirjian score + HJV                                   | 0.02 (−0.26 to 0.30) | 0.89 | 0.0007 (−0.003 to 0.004) | 0.70 |
| Demirjian score + NGAL                                  | 0.02 (−0.26 to 0.30) | 0.89 | 0.0007 (−0.003 to 0.004) | 0.70 |
| Demirjian score + TIMP2 and IGFBP7                     | -0.05 (−0.35 to 0.25) | 0.76 | 0.005 (−0.006 to 0.0157) | 0.41 |

$^a$The ability of a risk marker to more accurately stratify individuals into higher or lower risk categories was investigated by NRI. We reclassified the patients who had subsequent 90-day mortality or who did not by using a priori risk categories of <50% and >50% for the risk of 90-day mortality.

$^b$The $p$ value for increase in NRI in a model with biomarker combined with Demirjian score compared with Demirjian score alone.

cFGF-23, log C-terminal fibroblast factor-23; CI, confidence interval; HJV, hemoujuvelin; IGF, insulin-like growth factor; KIM, kidney injury molecule; NGAL, neutrophil-gelatinase-associated lipocalin; TIMP2, tissue inhibitor of metalloproteinase 2; IGFBP7, insulin-like growth-factor-binding protein 7.
study, performed statistical analysis and contributed to data collection, data interpretation, and critical revision of the manuscript. SC and TS contributed to interpretation and critical revision of the manuscript. All authors reviewed the manuscript. All authors read and approved the final manuscript. We also express our sincere gratitude to all staff of the Taiwan Clinical Trial Consortium, TCTC.

**Conflict of interest statement**
The authors declare that there is no conflict of interest.

**Funding**
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by Taiwan National Science Council [104-2314-B-002-125-MY3, 106-2314-B-002 -166-MY3,107-2314-B-002-026-MY3], National Health Research Institutes [PH-102-SP-09], National Taiwan University Hospital [106-FTN20, 106-P02,UN106-014,106-S3582,107-S3809,107-T02,PC1246, VN109-09,109-S4634,UN109-041 ] and Ministry of Science and Technology (MOST) of the Republic of China (Taiwan) [grant number, MOST 106-2321-B-182-002].

**ORCID iD**
Che-Hsiung Wu https://orcid.org/0000-0001-6164-6655

**Supplemental material**
Supplemental material for this article is available online.

**References**
1. Hsu CY, Ordonez JD, Chertow GM, et al. The risk of acute renal failure in patients with chronic kidney disease. *Kidney Int* 2008; 74: 101–107.
2. Chawla LS, Eggers PW, Star RA, et al. Acute kidney injury and chronic kidney disease as interconnected syndromes. *N Engl J Med* 2014; 371: 58–66.
3. Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and perspectives. *Lancet* 2013; 382: 260–272.
4. Kellum JA and Hoste EA. Acute kidney injury: epidemiology and assessment. *Scand J Clin Lab Invest Suppl* 2008; 241: 6–11.
5. Li PK, Burdmann EA and Mehta RL; World Kidney Day Steering Committee. Acute kidney injury: global health alert. *Curr Opin Nephrol Hypertens* 2013; 22: 253–258.
6. Wu VC, Huang TM, Lai CF, et al. Acute-on-chronic kidney injury at hospital discharge is associated with long-term dialysis and mortality. *Kidney Int* 2011; 80: 1222–1230.
7. Ronco C, Ricci Z, De Backer D, et al. Renal replacement therapy in acute kidney injury: controversy and consensus. *Crit Care* 2015; 19: 146.
8. Zarbock A, Kellum JA, Schmidt C, et al. Effect of early vs delayed initiation of renal replacement therapy on mortality in critically ill patients with acute kidney injury: the ELAIN randomized clinical trial. *JAMA* 2016; 315: 2190–2199.
9. Hsu CY, Chertow GM, McCulloch CE, et al. Nonrecovery of kidney function and death after acute on chronic renal failure. *Clin J Am Soc Nephrol* 2009; 4: 891–898.
10. Polichnowski AJ. Microvascular rarefaction and hypertension in the impaired recovery and progression of kidney disease following AKI in preexisting CKD states. *Am J Physiol Renal Physiol* 2018; 315: F1513–F1518.
11. Donate-Correa J, Muros de Fuentes M, Mora-Fernandez C, et al. Pathophysiological implications of fibroblast growth factor-23 and Klotho and their potential role as clinical biomarkers. *Clin Chem* 2014; 60: 933–940.
12. Brown JR, Katz R, Ix JH, et al. Fibroblast growth factor-23 and the long-term risk of hospital-associated AKI among community-dwelling older individuals. *Clin J Am Soc Nephrol* 2014; 9: 239–246.
13. Leaf DE, Wolf M, Waikar SS, et al. FGF-23 levels in patients with AKI and risk of adverse outcomes. *Clin J Am Soc Nephrol* 2012; 7: 1217–1223.
14. Wu VC, Shiao CC, Chi NH, et al. Outcome prediction of acute kidney injury biomarkers at initiation of dialysis in critical units. *J Clin Med* 2018; 7: 202.
15. Edmonston D and Wolf M. FGF23 at the crossroads of phosphate, iron economy and erythropoiesis. *Nat Rev Nephrol* 2019; 16: 7–19.
16. Endre ZH, Pickering JW, Walker RJ, et al. Improved performance of urinary biomarkers of acute kidney injury in the critically ill by stratification for injury duration and baseline renal function. *Kidney Int* 2011; 79: 1119–1130.
26. Wang JJ, Chi NH, Huang TM
Neutrophil gelatinase-associated lipocalin and acute kidney injury after cardiac surgery: the effect of baseline renal function on diagnostic performance. Clin J Am Soc Nephrol 2010; 5: 211–219.

27. Eisen MB, Spellman PT, Brown PO, et al. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 1998; 95: 14863–14868.

28. Wu VC, Lo SC, Chen YL, et al. Endothelial progenitor cells in primary aldosteronism: a biomarker of severity for aldosterone vasculopathy and prognosis. J Clin Endocrinol Metab 2011; 96: 3175–3183.

29. Wu VC, Lai CF, Shiao CC, et al. Effect of diuretic use on 30-day postdialysis mortality in critically ill patients receiving acute dialysis. PLoS One 2012; 7: e30836.

30. Hin LY, Lau TK, Rogers MS, et al. Dichotomization of continuous measurements using generalized additive modelling–application in predicting intrapartum caesarean delivery. Stat Med 1999; 18: 1101–1110.

31. Wu VC, Chang CH, Wang CY, et al. Risk of fracture in primary aldosteronism: a population-based cohort study. J Bone Miner Res 2017; 32: 743–752.

32. Wu VC, Chueh SJ, Chen L, et al. Risk of new-onset diabetes mellitus in primary aldosteronism: a population study over 5 years. J Hypertens 2017; 35: 1698–1708.

33. Donadio C. Effect of glomerular filtration rate impairment on diagnostic performance of neutrophil gelatinase-associated lipocalin and B-type natriuretic peptide as markers of acute cardiac and renal failure in chronic kidney disease patients. Crit Care 2014; 18: R39.

34. Doi K, Urata M, Katagiri D, et al. Plasma neutrophil gelatinase-associated lipocalin in acute kidney injury superimposed on chronic kidney disease after cardiac surgery: a multicenter prospective study. Crit Care 2013; 17: R270.

35. Kim HY, Kim CS, Bae EH, et al. Clinical significance of the interval change of plasma neutrophil gelatinase-associated lipocalin in acute kidney injury and acute kidney injury superimposed on chronic kidney disease. Chonnam Med J 2019; 55: 68–69.

36. Leaf DE, Siew ED, Eisenga MF, et al. Fibroblast growth factor 23 associates with death in critically ill patients. Clin J Am Soc Nephrol 2018; 13: 531–541.

37. Rossaint J, Oehmichen J, Van Aken H, et al. FGF23 signaling impairs neutrophil recruitment and host defense during CKD. J Clin Invest 2016; 126: 962–974.

38. Singh S, Grabner A, Yanucil C, et al. Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease. Kidney Int 2016; 90: 985–996.

39. Cortazar AC, Melero JIC, Bansell JC, et al. [Mixed cryoglobulinemia and chronic non-A
40. Bagshaw SM, Laupland KB, Doig CJ, et al. Prognosis for long-term survival and renal recovery in critically ill patients with severe acute renal failure: a population-based study. Crit Care 2005; 9: R700–R709.

41. Khosla N, Soroko SB, Chertow GM, et al. Preexisting chronic kidney disease: a potential for improved outcomes from acute kidney injury. Clin J Am Soc Nephrol 2009; 4: 1914–1919.

42. Pan HC, Wu PC, Wu VC, et al. A nationwide survey of clinical characteristics, management, and outcomes of acute kidney injury (AKI) - patients with and without preexisting chronic kidney disease have different prognoses. Medicine (Baltimore) 2016; 95: e4987.

43. Groeneveld AB, Tran DD, Van der Meulen J, et al. Acute renal failure in the medical intensive care unit: predisposing, complicating factors and outcome. Nephron 1991; 59: 602–610.

44. Cerda J, Cerda M, Kilcullen P, et al. In severe acute kidney injury, a higher serum creatinine is paradoxically associated with better patient survival. Nephrol Dial Transplant 2007; 22: 2781–2784.

45. Sawhney S, Marks A, Fluck N, et al. Intermediate and long-term outcomes of survivors of acute kidney injury episodes: a large population-based cohort study. Am J Kidney Dis 2017; 69: 18–28.

46. Noble JS, MacKirdy FN, Donaldson SI, et al. Renal and respiratory failure in Scottish ICUs. Anaesthesia 2001; 56: 124–129.

47. Coca SG, Singanamala S and Parikh CR. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int 2012; 81: 442–448.

48. Ishani A, Xue JL, Himmelfarb J, et al. Acute kidney injury increases risk of ESRD among elderly. J Am Soc Nephrol 2009; 20: 223–228.

49. Pannu N, James M, Hemmelgarn BR, et al. Modification of outcomes after acute kidney injury by the presence of CKD. Am J Kidney Dis 2011; 58: 206–213.

50. Chertow GM, Soroko SH, Paganini EP, et al. Mortality after acute renal failure: models for prognostic stratification and risk adjustment. Kidney Int 2006; 70: 1120–1126.

51. Mehta RL, Pascual MT, Gruta CG, et al. Refining predictive models in critically ill patients with acute renal failure. J Am Soc Nephrol 2002; 13: 1350–1357.

52. Lins RL, Elseviers MM, Daelemans R, et al. Re-evaluation and modification of the Stuivenberg Hospital Acute Renal Failure (SHARF) scoring system for the prognosis of acute renal failure: an independent multicentre, prospective study. Nephrol Dial Transplant 2004; 19: 2282–2288.